O’Sullivan B, Huang SH, Su J, Garden AS, Sturgis EM, Dahlstrom K, et al. Development and validation of a staging system for HPV-related oropharyngeal cancer by the international collaboration on Oropharyngeal cancer network for staging (ICON-S): a multicentre cohort study. Lancet Oncol. 2016;17(4):440–51.
Article
Google Scholar
Trosman SJ, Koyfman SA, Ward MC, Al-Khudari S, Nwizu T, Freskovich JF, et al. Effect of human papillomavirus on patterns of distant metastatic failure in oropharyngeal squamous cell carcinoma treated with chemoradiotherapy. JAMA Otolaryngol head neck Surg. 2015;141(5):457–62.
Article
Google Scholar
Haddad R, O’Neill A, Rabinowits G, Tishler R, Khuri F, Adkins D, et al. Induction chemotherapy followed by concurrent chemoradiotherapy (sequential chemoradiotherapy) versus concurrent chemoradiotherapy alone in locally advanced head and neck cancer (PARADIGM): a randomized phase 3 trial. Lancet Oncol. 2013;14:257–64.
Article
CAS
Google Scholar
Cohen EEW, Karrison T, Kocherginksy M, Mueller J, Egan R, Huang CH, et al. Phase III randomized trial of induction chemotherapy in patients with N2 or N3 locally advanced head and neck Cancer. J Clin Oncol. 2014;32(25):2735–43.
Article
CAS
Google Scholar
Hitt R, Grau JJ, Lopez-Póusa A, Berrocal A, García-Girón C, et al. A randomized phase III trial comparing induction chemotherapy followed by chemoradiotheapy versus chemoradiotherapy alone as treatment of unresectable head and neck cancer. Ann Oncol. 2014;25:216–25.
Article
CAS
Google Scholar
Pignon JP, le Maître A, Maillard E, Bourhis J. MACH-NC Collaborative Group. Meta-analysis of chemotherapy in head and neck cancer (MACH-NC): an update on 93 randomised trials and 17,346 patients. Radiother Oncol. 2009;92(1):4–14.
Article
Google Scholar
Blanchard P, Landais C, Petit C, Zhang Q, Grégoire E, Tobias J, et al. Meta-analysis of chemotherapy in head and neck cancer (MACH-NC): an update on 100 randomized trials and 19,248 patients, on behalf of MACH-NC group. Ann Oncol. 2016;27(Suppl 6):abstr 950O.
Google Scholar
Geoffrois L, Martin L, De Raucourt D, Shan Sun X, Tao Y, et al. Induction Chemotheapy followed by Cetuximab radiotherapy is not superior to concurrent Chemoradiotherapy for head and neck carcinomas: results of the GORTEC 2007–02 phase III randomized trial. J Clin Oncol. 2018;36:3077–83.
Article
CAS
Google Scholar
Kiong KL, de Souza NN, Sultana R, Iyer NG. Meta-analysis of induction chemotherapy as a selection marker for chemoradiation in the head and neck. Laryngoscope. 2018;128(7):1594–601.
Article
Google Scholar
Marur S, Li S, Cmelak AJ, Gillison ML, Zhao WJ, Ferris RL, et al. E1308: phase II trial of induction chemotherapy followed by reduced-dose radiation and weekly cetuximab in patients with HPV-associated resectable squamous cell carcinoma of the oropharynx- ECOG-ACRIN Cancer research group. J Clin Oncol. 2017;35(5):490–7.
Article
CAS
Google Scholar
Gillison ML, Trotti AM, Harris J, Eisbruch A, Harari PM, Adelstein DJ, et al. Radiotherapy plus cetuximab or cisplatin in human papillomavirus-positive oropharyngeal cancer (NRG oncology RTOG 1016): a randomised, multicentre, non-inferiority trial. Lancet. 2019;393(10166):40–50.
Article
CAS
Google Scholar
Wolf GT, Hong WK, Fisher SG, Hillman R, Spaulding M, et al. The Department of Veterans Affairs Laryngeal Cancer Study Group. Induction chemotherapy plus radiation compared with surgery plus radiation in patient with advanced laryngeal cancer. N Engl J Med. 1991;324:1685–90.
Article
Google Scholar
Blanchard P, Bourhis J, Lacas B, Posner MR, Vermorken JB, et al. Taxane-cisplatin-fluorouracil as induction chemotherapy in locally advanced head and neck cancers: an individual patient data meta-analysis of the meta-analysis of chemotherapy in head and neck cancer group. J Clin Oncol. 2013;31(23):2854–60.
Article
CAS
Google Scholar
Haddad R, Tishler R, Wirth L, Norris CM, Goguen L, et al. rate of pathologic complete responses to docetaxel, cisplatin, and fluorouracil induction chemotherapy in patients with squamous cell carcinoma of the head and neck. Arch Otolaryngol Head Neck Surg. 2006;132(6):678–81.
Article
Google Scholar
Lefebvre JL, Pointreau Y, Rolland F, Alfonsi M, Baudoux A, Sire C, et al. Induction chemotherapy followed by either chemoradiotherapy or bioradiotherapy for larynx preservation: the TREMPLIN randomized phase II study. J Clin Oncol. 2013;31(7):853–9.
Article
CAS
Google Scholar
Bossi P, Lo Vullo S, Guzzo M, Mariani L, Granata R, et al. Preoperative chemotherapy in advanced resectable OCSCC: long-term results of a randomized phase III trial. Ann Oncol. 2014;25:462–6.
Article
CAS
Google Scholar
Zhong LP, Zhang CP, Ren GX, Wei G, William WN Jr, et al. randomized phase III trial of induction chemotherapy with docetaxel, cisplatin, and fluorouracil followed by surgery versus up-front surgery in locally advanced resectable oral squamous cell carcinoma. J Clin Oncol. 2013;31:744–51.
Article
CAS
Google Scholar
Marta GN, Riera R, Bossi P, Lai-ping Z, Licitra L, et al. induction chemotherapy prior to surgery with or without postoperative radiotherapy for oral cavity cancer patients: systematic review and meta-analysis. Eur J Cancer. 2015;51(17):2596–603.
Article
Google Scholar
Ferris RL, Blumenschein G Jr, Fayette J, Guigay J, Colevas AD, Licitra L, et al. Nivolumab for recurrent squamous-cell carcinoma of the head and neck. N Engl J Med. 2016;375(19):1856–67.
Article
Google Scholar
Cohen EEW, Soulières D, Le Tourneau C, Dinis J, Licitra L, Ahn MJ, et al. Pembrolizumab versus methotrexate, docetaxel, or cetuximab for recurrent or metastatic head-and-neck squamous cell carcinoma (KEYNOTE-040): a randomized, open-label, phase 3 study. Lancet. 2019;393:156–67.
Article
CAS
Google Scholar
Rischin D, Harrington KJ, Greil R, Soulieres D, Tahara M, de Castro G, et al. Protocol-specified final analysis of the phase 3 KEYNOTE-048 trial of pembrolizumab (pembro) as first-line therapy for recurrent/metastatic head and neck squamous cell carcinoma (R/M HNSCC). J Clin Oncol. 2019;37(15_suppl):6000.
Vermorken JB, Mesia R, Rivera F, Remenar E, Kawecki A, Rottey S, et al. Platinum-based chemotherapy plus cetuximab in head and neck cancer. N Engl J Med. 2008;359:1116–27.
Article
CAS
Google Scholar
Cohen EEW, Soulières D, Le Tourneau C, Dinis J, Licitra L, Ahn MJ, et al. Health-related quality of life (HRQoL) of pembrolizumab (pembro) vs standard of care (SOC) for recurrent/metastatic head and neck squamous cell carcinoma (R/M HNSCC) in KEYNOTE-040. J Clin Oncol. 2018;36(15_suppl):6013.
Article
Google Scholar
Stefani AD, Forna G, Ragona R, Cavallo G, Bussi M, Usai A, et al. Improved survival with perilymphatic interleukin 2 in patients with resectable squamous cell carcinoma of the oral cavity and oropharynx. Cancer. 2002;95:90–7.
Article
Google Scholar
Uppaluri R, Zolkind P, Lin T, Nussenbaum B, Jackson RS, Rich J, et al. Neoadjuvant pembrolizumab in surgically resectable, locally advanced HPV negative head and neck squamous cell carcinoma (HNSCC). J Clin Oncol. 2017;35(15 Suppl):abstr 6012.
Article
Google Scholar
Wise-Draper TM, Old MO, Worden FP, O’Brien PE, Cohen EEW, Dunlap N, et al. Phase II multi-site investigation of neoadjuvant pembrolizumab and adjuvant concurrent radiation and pembrolizumab with or without cisplatin in resected head and neck squamous cell carcinoma. J Clin Oncol. 2018;36(15_suppl):6017.
Horton J, Knochelmann H, Armeson K, Kaczmar J, Paulos C, Neskey D. Neoadjuvant presurgical PD-1 inhibition in oral cavity squamous cell carcinoma. J Clin Oncol. 2019;37(15_suppl):2574.
Lauber K, Dunn L. Immunotherapy mythbusters in head and neck cancer: the abscopal effect and pseudoprogression. Am Soc Clin Oncol Educ Book. 2019;39:352–63.
Article
Google Scholar
Knochelmann H, Horton JD, Meek M, Krieg C, Timmers CD, Romeo M, et al. Immune signatures associated with response to neoadjuvant PD-1 blockade in oral cavity cancer. J Clin Oncol. 2019;37(15_suppl):6055.
Horton J, Knochelmann H, Bobian M, Kaczmar J, Paulos J, Neskey D. Post-nivolumab neutrophil-to-lymphocyte ratio predicts response to neoadjuvant presurgical PD-1 inhibition in oral cavity cancer. Poster presented at: American Association for Cancer Research (AACR)-American Head and Neck Society (AHNS) Head and Neck Cancer Conference. April 29–30, 2019. Austin, TX.
Ferris RL, Gonçalves A, Baxi AA, Martens UM, Gauthier H. An open-label, multicohort, phase 1/2 study in patients with virus-associated cancers (CheckMate 358): safety and efficacy of neoadjuvant nivolumab in squamous cell carcinoma of the head and neck (SCCHN). Ann Oncology. 2017;28(suppl_5):v605–V649.
Google Scholar
Ferrarotto R, Bell D, Rubin ML, Lee JJ, Johnson JM, Goepfert G, et al. Checkpoint inhibitors assessment in oropharynx cancer (CIAO): Safety and interim results. J Clin Oncol. 2019;37(15_suppl):6008.
Zuur CL, Elbers JBW, Vos JL, van der Leun A, Qiao X, Karakullukcu B, et al. Feasibility and toxicity of neoadjuvant nivolumab with or without ipilimumab prior to extensive (salvage) surgery in patients with advanced head and neck cancer (the IMCISION trial, NCT03003637). J Clin Oncol. 2019;37(15_suppl):2575.
Forde PM, Chaft JE, Smith KN, Anagnostou V, Cottrell TR, Hellmann MD, et al. Neoadjuvant PD-1 blockade in resectable lung cancer. N Engl J med. 2018;378:1976–86.
Article
CAS
Google Scholar
Wrangle JM, Valcheti V, Patel MR, Garrett-Mayer E, Hill EG, Ravenel JG, et al. ALT-803, an IL-15 superagonist, in combination with nivolumab in patients with metastatic non-small cell lung cancer: a non-randomized, open-label, phase 1b trial. Lancet Oncol. 2018;19(5):694–704.
Article
CAS
Google Scholar